T-Guard: Phase Ib/IIa started

Xenikos began an open-label, European Phase Ib/IIa trial to evaluate 2 mg/m 2 IV T-Guard in about 20 patients with severe steroid-refractory acute GvHD. T-Guard has Orphan Drug designation in the U.S....